Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study.

Lorena Carballo-Folgoso Rut Alvarez-VelascoRebeca LorcaAndrés Castaño-GarcíaJavier CuevasMaría Luisa González-DiéguezMaría MartínCarmen Álvarez-NavascuésValle CadahíaCésar MorísManuel RodríguezMaria Varela

Published in: Liver international : official journal of the International Association for the Study of the Liver (2021)

The incidence of cardiovascular events in HCC patients treated with SOR is higher than expected. Multidisciplinary approach and clinical tools like CARDIOSOR scale could be helpful to manage these patients.

Keyphrases

cardiovascular events
coronary artery disease
cardiovascular disease
clinical practice
newly diagnosed
end stage renal disease
ejection fraction
risk factors
peritoneal dialysis
type diabetes
patient reported